retatrutide triple agonist glp-1 gip glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide | GLP-1R/GIPR/GCGR ligand |
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 25 - Nov 30










:max_bytes(150000):strip_icc():focal(749x0:751x2)/smoothie-king-store-ozempic-102824-4325a852dde54011a053a779d9d8c296.jpg)












